Avidity Biosciences Stock Performance
| RNA Stock | USD 72.72 0.21 0.29% |
Avidity Biosciences has a performance score of 20 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Avidity Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Avidity Biosciences is expected to be smaller as well. Avidity Biosciences right now shows a risk of 0.27%. Please confirm Avidity Biosciences treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to decide if Avidity Biosciences will be following its price patterns.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Avidity Biosciences are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Avidity Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.26 | Five Day Return 0.65 | Year To Date Return 1.15 | Ten Year Return 155.89 | All Time Return 155.89 |
1 | Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44 | 11/19/2025 |
2 | Disposition of 1542 shares by Hughes Steven George of Avidity Biosciences at 46.66 subject to Rule 16b-3 | 11/28/2025 |
3 | Genomic Testing Cooperative to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology Annual Meeting in Orlando | 12/02/2025 |
4 | Hummingbird Diagnostics Publishes Study on RNA Biomarker Methylation in Liquid Biopsies | 12/16/2025 |
5 | Acuitas Therapeutics Expands Collaboration with RNA Technologies Therapeutics Through Strategic Investment | 01/08/2026 |
6 | Disposition of 1965 shares by Teresa McCarthy of Avidity Biosciences at 72.23 subject to Rule 16b-3 | 01/09/2026 |
7 | 7.5 Billion RNA Sequencing Services Market Opportunity Outlook, 2035 | 01/12/2026 |
8 | Transform Your Strategic Vision New RNA Targeting Small Molecule Drug Discovery Market Report Unveils Unprecedented Growth Opportunities | 01/15/2026 |
9 | Genomics Market Research Report 2025 Innovations are Accelerating the Transition to Faster Diagnostics, Scalable Biomanufacturing, and Precision Therapies | 01/20/2026 |
10 | Exploring Investment Opportunities in the Expanding RNA Therapy Clinical Trials Market A USD 4.28 Billion Valuation by 2031 | 01/21/2026 |
11 | Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit | 01/23/2026 |
12 | 23.65 Bn RNA Analysis Market Trends Analysis and Growth Forecast to 2033 | 01/30/2026 |
13 | Avidity Biosciences Announces Expected Record Date for Spin-Off | 02/03/2026 |
| Begin Period Cash Flow | 185.4 M | |
| Total Cashflows From Investing Activities | -854.2 M |
Avidity Biosciences Relative Risk vs. Return Landscape
If you would invest 6,978 in Avidity Biosciences on November 6, 2025 and sell it today you would earn a total of 294.00 from holding Avidity Biosciences or generate 4.21% return on investment over 90 days. Avidity Biosciences is generating 0.068% of daily returns assuming volatility of 0.268% on return distribution over 90 days investment horizon. In other words, 2% of stocks are less volatile than Avidity, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Avidity Biosciences Target Price Odds to finish over Current Price
The tendency of Avidity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 72.72 | 90 days | 72.72 | about 12.13 |
Based on a normal probability distribution, the odds of Avidity Biosciences to move above the current price in 90 days from now is about 12.13 (This Avidity Biosciences probability density function shows the probability of Avidity Stock to fall within a particular range of prices over 90 days) .
Avidity Biosciences Price Density |
| Price |
Predictive Modules for Avidity Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Avidity Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Avidity Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Avidity Biosciences is not an exception. The market had few large corrections towards the Avidity Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Avidity Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Avidity Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 0.13 | |
σ | Overall volatility | 0.95 | |
Ir | Information ratio | 0.07 |
Avidity Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Avidity Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Avidity Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (467.32 M). | |
| Avidity Biosciences has about 398.22 M in cash with (300.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Avidity Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Avidity Biosciences Announces Expected Record Date for Spin-Off |
Avidity Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Avidity Stock often depends not only on the future outlook of the current and potential Avidity Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Avidity Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 111.6 M | |
| Cash And Short Term Investments | 1.5 B |
Avidity Biosciences Fundamentals Growth
Avidity Stock prices reflect investors' perceptions of the future prospects and financial health of Avidity Biosciences, and Avidity Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avidity Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (15.13) % | ||||
| Current Valuation | 9.11 B | ||||
| Shares Outstanding | 154.48 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 5.80 X | ||||
| Price To Sales | 538.47 X | ||||
| Revenue | 10.9 M | ||||
| Gross Profit | (467.32 M) | ||||
| EBITDA | (376.16 M) | ||||
| Net Income | (322.3 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 6.8 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.85 X | ||||
| Cash Flow From Operations | (300.87 M) | ||||
| Earnings Per Share | (4.19) X | ||||
| Market Capitalization | 11.24 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (893.07 M) | ||||
| Working Capital | 1.44 B | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
About Avidity Biosciences Performance
By analyzing Avidity Biosciences' fundamental ratios, stakeholders can gain valuable insights into Avidity Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avidity Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avidity Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.19) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.21) | (0.19) | |
| Return On Equity | (0.26) | (0.25) |
Things to note about Avidity Biosciences performance evaluation
Checking the ongoing alerts about Avidity Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avidity Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (467.32 M). | |
| Avidity Biosciences has about 398.22 M in cash with (300.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Avidity Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Avidity Biosciences Announces Expected Record Date for Spin-Off |
- Analyzing Avidity Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avidity Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Avidity Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avidity Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avidity Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avidity Biosciences' stock. These opinions can provide insight into Avidity Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |